HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.1%

Neg 0% Neu 91.1% Pos 0%

HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.